IRLAB Therapeutics: Takeaways from the CMD - ABG

CMD in Stockholm focused on mesdopetam
Potential Ph 3 programme outlined by KOL
End-of-phase 2 meeting with FDA in H1'24e


CMD in Stockholm to show steps foward with mesdopetam

Yesterday IRLAB Therapeutics hosted its 2023 capital markets day (CMD). IRLAB's Management team gave a nice overview of the company, including a detailed overview of the Ph 2b results in PD-LIDs with mesdopetam. The CMD also hosted a presentation from KOL Karl Kieburtz, MD, MHD, Professor in Neurology, where he outlined the potential regulatory steps forward regarding future Ph 3 development for mesdopetam.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/irlab-therapeutics/Equity-research/2023/10/irlab-therapeutics---takeaways-from-the-cmd/